The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

(2021) Ioana Gherghescu et al.   Pharmaceutics

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

(2021) Yannick Vandenplas et al.   Pharmaceuticals

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

(2020) HoUng Kim et al.   DRUGS

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

(2020) Tom Kovitwanichkanont et al.   INTERNAL MEDICINE JOURNAL

P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience

(2020) D Rosembert et al.   Journal of Crohns & Colitis

Strategies to achieve fairer prices for generic and biosimilar medicines

(2020) Alessandra Ferrario et al.   BMJ-British Medical Journal

TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis

(2020) Paolo Gisondi et al.   Expert Review of Clinical Immunology

Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch

(2020) Chiara Gasteiger et al.   RHEUMATOLOGY INTERNATIONAL

Physicians’ perceptions of the uptake of biosimilars: a systematic review

(2020) Kati Sarnola et al.   BMJ Open

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb

(2020) Shubha Bhat et al.   Journal of Managed Care & Specialty Pharmacy

Biosimilars in oncology: key role of nurses in patient education

(2020) Cornelius F Waller et al.   Future Oncology

‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?

(2019) Marc Scherlinger et al.   ANNALS OF THE RHEUMATIC DISEASES

P544 Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study

(2019) A Hastier-De Chelle et al.   Journal of Crohns & Colitis

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice

(2019) Zohra Layegh et al.   International Journal of Rheumatic Diseases

Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases

(2019) Christopher J. Edwards et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

E020 Patient experience of switching from Enbrel to Benapali

(2019) Sandra Robinson et al.   RHEUMATOLOGY

E014 Patient experience of switching to biosimilar Benepali

(2019) Nadia Ahmad et al.   RHEUMATOLOGY

204 Switching to biosimilar rituximab: a real world study

(2019) Muhammad K Nisar   RHEUMATOLOGY

E007 Etanercept (ETN) biosimilar (Benapali - SB4) switches in inflammatory arthritis patients at Wrightington Hospital

(2019) Perpetual C Uke et al.   RHEUMATOLOGY

Current perspectives on biosimilars

(2019) Frank K. Agbogbo et al.   JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY

The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch

(2019) Chiara Gasteiger et al.   ARTHRITIS CARE & RESEARCH

Health information overload among health consumers: A scoping review

(2019) Israa Khaleel et al.   PATIENT EDUCATION AND COUNSELING

Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease

(2019) Vincent Haghnejad et al.   DIGESTIVE AND LIVER DISEASE

The Clinical Implications of Nocebo Effects for Biosimilar Therapy

(2019) Luana Colloca et al.   Frontiers in Pharmacology

Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

(2019) Nicolas Petitdidier et al.   DIGESTIVE AND LIVER DISEASE

Overcoming barriers to biosimilars in inflammatory arthritis

(2019) Jonathan Kay   Nature Reviews Rheumatology

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars

(2018) Mourad F. Rezk et al.   ADVANCES IN THERAPY

Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations

(2018) Monika Mueller et al.   BMC Medical Research Methodology

The nocebo effect challenges the non-medical infliximab switch in practice

(2018) N. W. Boone et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Short article

(2018) Lisette Binkhorst et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

065 Personalising care: the use of anti-drug antibodies and drug trough levels is a safe and cost-effective treatment strategy in spondyloarthritis

(2018) S R Dubash et al.   RHEUMATOLOGY

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

(2018) Raguprakash Ratnakumaran et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Acceptance Rate And Sociological Factors Involved In The Switch From Originator To Biosimilar Etanercept (SB4)

(2018) Marc Scherlinger et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Open-Label Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: 6-Month Results From a Controlled Cohort Study

(2018) Lieke Tweehuysen et al.   Arthritis & Rheumatology

Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects

(2018) Keith J. Petrie et al.   Annual Review of Psychology

The nocebo effect: a clinical challenge in the era of biosimilars

(2018) Lieven Pouillon et al.   Expert Review of Clinical Immunology

OUP accepted manuscript

(2018)   Journal of Crohns & Colitis

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies

(2018) Johlee S. Odinet et al.   Journal of Managed Care & Specialty Pharmacy

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

(2018) Vincent Germain et al.   ANNALS OF THE RHEUMATIC DISEASES

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

(2018) Nikolas Plevris et al.   DIGESTIVE DISEASES AND SCIENCES

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

(2017) Marc Scherlinger et al.   JOINT BONE SPINE

Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

(2017) Violeta Razanskaite et al.   Journal of Crohns & Colitis

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Medical specialists' attitudes to prescribing biosimilars

(2017) Amy Hemmington et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany

(2017) Emma Sullivan et al.   PLoS One

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

(2017) Lieke Tweehuysen et al.   Arthritis & Rheumatology

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

(2016) Silvio Danese et al.   Journal of Crohns & Colitis

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

(2016) Lisa J. T. Smits et al.   Journal of Crohns & Colitis

Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients Adherence Using a Self-report Questionnaire

(2016) A.-L. Betegnie et al.   JOURNAL OF RHEUMATOLOGY

Biosimilars: A consideration of the regulations in the United States and European union

(2016) Justin Daller   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

(2016) Ira Jacobs et al.   Patient Preference and Adherence

Patient-centred care in established rheumatoid arthritis

(2015) M.J.H. Voshaar et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Seeing is believing: Impact of social modeling on placebo and nocebo responding.

(2015) Kate Faasse et al.   HEALTH PSYCHOLOGY

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

(2015) Yoon Suk Jung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Unhelpful information about adverse drug reactions

(2014) K. Tan et al.   BMJ-British Medical Journal

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

The nocebo effect: patient expectations and medication side effects

(2013) Kate Faasse et al.   POSTGRADUATE MEDICAL JOURNAL

The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects

(2012) Kate Faasse et al.   PSYCHOSOMATIC MEDICINE

Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre–post observational study

(2012) Kate Faasse et al.   BMJ Open

Effect of a Symptom Diary on Symptom Frequency and Intensity in Healthy Subjects

(2010) R. FERRARI et al.   JOURNAL OF RHEUMATOLOGY

How does communication heal? Pathways linking clinician–patient communication to health outcomes

(2009) Richard L. Street et al.   PATIENT EDUCATION AND COUNSELING